| Study removed | Ramosetron | Placebo | Pooled relative risks(RRs) with 95% confidence interval(CI) | ||
---|---|---|---|---|---|---|
Events | Total | Events | Total | |||
Relief of overall IBS symptoms | None | 372 | 803 | 216 | 801 | 1.70 [1.48, 1.95] |
Matsueda K 2008a [25] | 249 | 540 | 145 | 536 | 1.70 [1.40, 2.06] | |
Matsueda K 2008b [26] | 329 | 702 | 188 | 697 | 1.73 [1.47, 2.03] | |
Fukudo S 2014 [22] | 314 | 656 | 190 | 653 | 1.64 [1.42, 1.89] | |
Fukudo S 2015 [23] | 224 | 511 | 125 | 517 | 1.80 [1.50, 2.15] | |
Relief of abdominal discomfort/pain | None | 368 | 803 | 259 | 801 | 1.41 [1.24, 1.59] |
Matsueda K 2008a [25] | 248 | 540 | 171 | 536 | 1.43 [1.22, 1.66] | |
Matsueda K 2008b [26] | 330 | 702 | 232 | 697 | 1.40 [1.23, 1.60] | |
Fukudo S 2014 [22] | 308 | 656 | 222 | 653 | 1.38 [1.20, 1.57] | |
Fukudo S 2015 [23] | 218 | 511 | 152 | 517 | 1.44 [1.22, 1.71] | |
Improvement in abnormal bowel habits | None | 358 | 803 | 205 | 801 | 1.72 [1.50, 1.98] |
Matsueda K 2008a [25] | 243 | 540 | 142 | 536 | 1.69 [1.38, 2.06] | |
Matsueda K 2008b [26] | 314 | 702 | 174 | 697 | 1.77 [1.52, 2.06] | |
Fukudo S 2014 [22] | 306 | 656 | 182 | 653 | 1.66 [1.44, 1.93] | |
Fukudo S 2015 [23] | 211 | 511 | 117 | 517 | 1.80 [1.46, 2.23] | |
Improvement in stool consistency | None | 184 | 439 | 106 | 432 | 1.71 [1.40, 2.08] |
Fukudo S 2014 [22] | 119 | 292 | 69 | 284 | 1.68 [1.31, 2.15] | |
Fukudo S 2015 [23] | 65 | 147 | 37 | 148 | 1.77 [1.27, 2.47] |